GHK-Cu
Copper tripeptide. GHK-Cu is not FDA approved for any use.
Key facts
- Class
- Copper tripeptide
- Also called
- copper peptide, copper tripeptide-1
- Vial sizes sold
- 50 mg, 100 mg, 200 mg
- Community-reported sizes
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Unclear
- Not named on the 2026 list
GHK-Cu guides
Explained
Questions
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Hair | 4 | 0 | 1 | Human observational evidence, 3 of 4Journal of cosmetic and laser therapy 2018, PMID 29482481 |
| Skin | 18 | 5 | 8 | Human RCT evidence, 4 of 4Archives of facial plastic surgery 2006, PMID 16847171 |
| Inflammation | 13 | 12 | 3 | Animal evidence, 2 of 4Frontiers in pharmacology 2025, PMID 40672369 |
| Injury recovery | Not in our ledger | Not in our ledger | 5 | Human RCT evidence, 4 of 4Wound repair and regeneration 1994, PMID 17147644 |
| Liver | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Longevity | 11 | 4 | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
GHK-Cu: a copper-bound tripeptide with a skin-care history
A recent systematic review defines GHK-Cu as the copper-bound form of a human tripeptide; the letters G, H and K stand for glycine, histidine and lysine.[19]
The same review proposes a mechanism: the peptide is released from collagen and SPARC as a signal fragment, and copper helps the enzymes that cross-link collagen.[19]
What the human evidence actually covers
The same review says the human literature is thin and fragmented: most randomized trials are small and test facial cosmetic creams.[19]
A separate review of anti-wrinkle peptides reaches the same conclusion about clinical data.[20]
The clearest human result found is an older randomized trial of a topical gel (lamin Gel) in diabetic foot ulcers: 98.5% median closure against 60.8% for vehicle.[17]
Regulatory path
Drugs@FDA has no GHK-Cu entry.[3]
In FDA's compounding categories, GHK-Cu was added back to category 1 except for injectable routes of administration.[4]
WADA does not name GHK-Cu. Its S0 catch-all covers substances with no human therapeutic approval, and this site has not verified GHK-Cu's approval status.[2]
Compared with
Common stacks
GHK-Cu is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is GHK-Cu FDA approved?
No. GHK-Cu is not FDA approved for any use. The FDA removed it (injectable form) from Category 2 on 15 Apr 2026.
How much water goes in a 50 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 25 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is GHK-Cu?
It is a copper complex of a short human tripeptide, used mainly in skin-care research.[19]
Is copper peptide the same as GHK-Cu?
Not always: the anti-wrinkle literature discusses GHK-Cu and Pal-GHK as separate ingredients, and a review notes clinical studies are surprisingly absent for them.[20]
Is there evidence for injected GHK-Cu?
The injected-route study found here is in rats after knee-ligament reconstruction: knee laxity was smaller than with saline at 6 weeks, with no significant difference at 12 weeks.[21]
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "GHK-Cu" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 4US compounding: GHK-Cu (non-injectable routes) is in FDA's 503A category 1 (under evaluation); the injectable-route nominations were withdrawn and removed from category 2.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 5Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018PMID 29482481Accessed 2 Oct 2026
- 6Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
- 7PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 16Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.Frontiers in pharmacology · 2025PMID 40672369Accessed 2 Oct 2026
- 17Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
- 18PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026PMID 42787770Accessed 2 Oct 2026
- 20Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.BioImpacts : BI · 2025PMID 39963574Accessed 2 Oct 2026
- 21Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
Found an error? Report a correction.